Format

Send to

Choose Destination
Med Mycol. 2011 Apr;49 Suppl 1:S77-81. doi: 10.3109/13693786.2010.499374. Epub 2010 Jul 7.

Newer combination antifungal therapies for invasive aspergillosis.

Author information

1
Department of Pediatrics, Division of Pediatric Infectious Diseases, Duke University, Durham, NC 27710, USA. stein022@mc.duke.edu

Abstract

Optimal therapy for invasive aspergillosis is unknown, and many clinicians have attempted to utilize a combination antifungal approach to improve outcomes. However, while numerous in vitro studies, animal models, and clinical reports suggest the possibility that combination antifungal therapy might offer improved results, there is no definitive accepted strategy. The currently available antifungals used in various combination approaches have not demonstrated clear improvement over monotherapy. The current classes of drugs targeting the cell wall and cell membrane may need adjunctive agents focused on separate cellular pathways, such as cell stress response or cellular signaling, to maximize efficacy. The calcineurin and the Hsp90 pathways are two such untouched arenas in which targeted manipulation may lead to great advances against aspergillosis.

PMID:
20608784
PMCID:
PMC4442698
DOI:
10.3109/13693786.2010.499374
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center